Abstract:Hepatitis B virus (HBV) is a challenge for global health services, affecting millions and leading thousands to end-stage liver disease each year. This comprehensive review explores the interactions between HBV and the host, examining their impact on clinical outcomes. HBV infection encompasses a spectrum of severity, ranging from acute hepatitis B to chronic hepatitis B, which can potentially progress to cirrhosis and hepatocellular carcinoma (HCC). Occult hepatitis B infection (OBI), characterized by low HBV DNA levels in hepatitis B surface antigen-negative individuals, can reactivate and cause acute hepatitis B. HBV genotyping has revealed unique geographical patterns and relationships with clinical outcomes. Moreover, single nucleotide polymorphisms (SNPs) within the human host genome have been linked to several clinical outcomes, including cirrhosis, HCC, OBI, hepatitis B reactivation, and spontaneous clearance. The immune response plays a key role in controlling HBV infection by eliminating infected cells and neutralizing HBV in the bloodstream. Furthermore, HBV can modulate host metabolic pathways involved in glucose and lipid metabolism and bile acid absorption, influencing disease progression. HBV clinical outcomes correlate with three levels of viral adaptation. In conclusion, the clinical outcomes of HBV infection could result from complex immune and metabolic interactions between the host and HBV. These outcomes can vary among populations and are influenced by HBV genotypes, host genetics, environmental factors, and lifestyle. Understanding the degrees of HBV adaptation is essential for developing region-specific control and prevention measures.

Terbufos poisoning in a dairy herd.

Viral hepatitis: Innovations and expectations

The acute effects of experimental short-term evening and night shifts on human circadian rhythm: the oral temperature, heart rate, serum cortisol and urinary catecholamines levels

A Simultaneous Access Design for Idle Processor Reactivation and the Detection of the Termination of a Parallel Activity

Mitochondria in the biology, pathogenesis, and treatment of hepatitis virus infections

Present and future management of viral hepatitis

Advances in Hepatitis B Treatment

A novel heterozygous mutation in desmoplakin gene in a Lebanese patient with Carvajal syndrome and tooth agenesis

Immunobiology and pathogenesis of hepatitis B virus infection

Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy

Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment.

HBV life cycle and novel drug targets

Hepatitis C Virus: Pathogenesis and Host Immune Response

Acute Hepatitis C: Current Status and Future Perspectives

A Global View to HBV Chronic Infection: Evolving Strategies for Diagnosis, Treatment and Prevention in Immunocompetent Individuals

Viral Biology and Immune Privilege in the Development of Extrahepatic Manifestations During Hepatitis E Virus Infection

Advances in multi-omics research on viral hepatitis

Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside

Advances in the Diagnosis and Monitoring of Hepatitis C Virus Infection

Host and HBV Interactions and Their Potential Impact on Clinical Outcomes

Interplay Between Hepatitis B Virus and the Innate Immune Responses:Implications for New Therapeutic Strategies